Anti-HTLV-1 tax antibody and tax-specific cytotoxic T lymphocyte are associated with a reduction in HTLV-1 proviral load in asymptomatic carriers

Journal of Medical Virology

Volumn 79, Issue 7, 2007, Pages 977-986

  Akimoto, Masaki ^a   Kozako, Tomohiro ^b   Sawada, Takashi ^c   Matsushita, Kakushi ^a   Ozaki, Atsuo ^a   Hamada, Heiichiro ^a   Kawada, Hideaki ^a   Yoshimitsu, Makoto ^a   Tokunaga, Masahito ^a   Haraguchi, Koichi ^a   Uozumi, Kimiharu ^b   Arima, Naomichi ^b   Tei, Chuwa ^b  

^a KAGOSHIMA UNIVERSITY HOSPITAL   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c EISAI CO LTD   (Japan)

Author keywords

Anti Tax antibody; Carrier; CTL; HTLV 1; Proviral load

Indexed keywords

TAX PROTEIN; VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; HUMORAL IMMUNITY; MALE; PROVIRUS; REAL TIME POLYMERASE CHAIN REACTION; T CELL LEUKEMIA; T CELL LYMPHOMA; VIRUS CARRIER; VIRUS LOAD;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; CARRIER STATE; FEMALE; GENE PRODUCTS, TAX; HTLV-I ANTIBODIES; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROVIRUSES; T-LYMPHOCYTES, CYTOTOXIC;

HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 34249910352     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20807     Document Type: Article

References (69)

1. Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, Strick D, Johnston MN, Corcoran C, Wurcel AG, Fitzpatrick CA, Feeney ME, Rodriguez WR, Basgoz N, Draenert R, Stone DR, Brander C, Goulder PJ, Rosenberg ES, Altfeld M, Walker BD. 2003. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 77:2081-2092.
2. Bangham CRM. 2002. Genetics and dynamics of the immune response to HTLV-I. Gann Monogr Cancer Res 50:397-402.
3. Bangham CRM. 2003. The immune control and cell-to-cell spread of human T-lymphotropic virus type 1. J Gen Virol 84:3177-3189.
4. Bangham C, Kermode A, Hall S, Daenke S. 1996. The cytotoxic T lymphocyte response to HTLV-I: The main determinant of disease? Semin Virol 7:41.
5. Bangham CR, Hall SE, Jeffery KJ, Vine AM, Witkover A, Nowak MA, Wodarz D, Usuku K, Osame M. 1999. Genetic control and dynamics of the cellular immune response to the human T-cell leukaemia virus, HTLV-I. Philos Trans R Soc Lond B Biol Sci 354:691-700.
6. + T-cell responses: Relationship to viral load in untreated HIV infection. J Virol 75:11983-11991.
7. + CTL clones from patients with HTLV-I-associated neurologic disease secrete proinflammatory cytokines, chemokines, and matrix metalloproteinase. J Immunol 159:2018-2025.
8. Bieganowska K, Hollsberg P, Buckle GJ, Lim DG, Greten TF, Schneck J, Altman JD, Jacobson S, Ledis SL, Hanchard B, Chin J, Morgan O, Roth PA, Hafler DA. 1999. Direct analysis of viral-specific CD8+ T cells with soluble HLA-A2/Tax 11-19 tetramer complexes in patients with human T-lymphotropic virus-associated myelopathy. J Immunol 162:1765-1771.
9. Daenke S, Kermode AG, Hall SE, Taylor G, Weber J, Nightingale S, Bangham CR. 1996. High activated and memory cytotoxic T-cell responses to HTLV-1 in healthy carriers and patients with tropical spastic paraparesis. Virology 217:139-146.
10. Ehrlich G, Greenberg S, Abbot M. 1990. Detection of human T-cell lymphoma/leukemia viruses. In: Innis M, Gelfand D, Suinsky J, White T, editors. PCR protocols. San Diego: Academic Press. pp 325-332.
11. Elovaara I, Koenig S, Brewah AY, Woods RM, Lehky T, Jacobson S. 1993. High human T cell lymphotropic virus type 1 (HTLV-1)-specific precursor cytotoxic T lymphocyte frequencies in patients with HTLV-1-associated neurological disease. J Exp Med 177: 1567-1573.
12. Etoh K, Tamiya S, Yamaguchi K, Okayama A, Tsubouchi H, Ideta T, Mueller N, Takatsuki K, Matsuoka M. 1997. Persistent clonal proliferation of human T-lymphotropic virus type I-infected cells in vivo. Cancer Res 57:4862-4867.
13. Gessain A, Barin F, Vermint JC, Gout O, Maurs L, Calender A, de The G. 1985. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 2:407-410.
14. + T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes. Blood 95:1386-1392.
15. Hino S, Yamaguchi K, Katamine S, Sugiyama H, Amagasaki T, Kinoshita K, Yoshida Y, Doi H, Tsuji Y, Miyamoto T. 1985. Mother-to-child transmission of human T-cell leukemia virus type-1. Jpn J Cancer Res 76:474-480.
16. Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI, Shirakawa S, Miyoshi I. 1981. Adult T-cell leukemia: Antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 78:6476-6480.
17. Hisada M, Okayama A, Tachibana N, Stuver SO, Spiegelman DL, Tsubouchi H, Mueller NE. 1998a. Predictors of level of circulating abnormal lymphocytes among human T-lymphotropic virus type I carriers in Japan. Int J Cancer 77:188-192.
18. Hisada M, Okayama A, Shioiri S, Spiegelman DL, Stuver SO, Mueller NE. 1998b. Risk factors for adult T-cell leukemia among carriers of human T-lymphotropic virus type I. Blood 92:3557-3561.
19. Hisada M, Okayama A, Spiegelman D, Mueller NE, Stuver SO. 2001. Sex-specific mortality from adult T-cell leukemia among carriers of human T-lymphotropic virus type I. Int J Cancer 91:497-499.
20. Ijichi S, Izumo S, Eiraku K, Machigashira R, Kubota M, Nagai M, Ikegami N, Kashio N, Umehara I, Maruyama I, Osame M. 1993. An autoaggressive process against bystander tissues in HTLV-I-infected individuals: A possible pathomechanism of HAM/TSP. Med Hypotheses 41:542-547.
21. Ishihara S, Okuyumn A, Stuver S, Horinouchi H, Shioiri S, Murai K, Kubota T, Yamashita R, Tachibana N, Tsubouchi H, Mueller N. 1994. Association of HTLV-I antibody profile of asymptomatic carriers with proviral DNA levels of peripheral blood mononuclear cells. J Acquir Immune Defic Syndr 7:199-203.
22. Jacobson S, Shida H, McFarlin DE, Fauci AS, Koenig S. 1990. Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature 348:245-248.
23. Jeffery KJ, Usuku K, Hall SE, Matsumoto W, Taylor GP, Procter J, Bunce M, Ogg GS, Welsh KI, Weber JN, Lloyd AL, Nowak MA, Nagai M, Kodama D, Izumo S, Osame M, Bangham CR. 1999. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) provirus load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci USA 96:3848-3853.
24. Jeffery KJ, Siddiqui AA, Bunce M, Lloyd AL, Vine AM, Witkover AD, Izumo S, Usuku K, Welsh KI, Osume M, Bangham CR. 2000. The influence of HLA class 1 alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection. J Immunol 165:7278-7284.
25. tax gene product of human T-lymphotropic virus type-I (HTLV-I) under various conditions of HTLV-I infection. Jpn J Cancer Res 80:1066-1071.
26. Kannagi M, Sugamura K, Sato H, Okochi K, Uchino H, Hinuma Y. 1983. Establishment of human cytotoxic T cell lines specific for human adult T cell leukemia virus-bearing cells. J Immunol 130:2942-2946.
27. Kannagi M, Sugamura K, Kinoshita K, Uchino H, Hinuma Y. 1984. Specific cytolysis of fresh tumor cells by an autologous killer T cell line derived from an adult T cell leukemia/lymphoma patient. J Immunol 133:1037-1041.
28. Kannagi M, Harada S, Maruyama I, Inoko H, Igarashi H, Kuwashima G, Sato S, Morita M, Kidokoro M, Sugimoto M, Funahashi S, Osame M, Shida H, Honjo T. 1991. Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV-1-infected cells. Int Immunol 3:761-767.
29. Kannagi M, Matsushita S, Harada S. 1993. Expression of the target antigen for cytotoxic T lymphocytes on adult T-cell leukemia cells. Int J Cancer 54:582-588.
30. Kannagi M, Matsushita S, Shida H, Harada S. 1994. Cytotoxic T cell response and expression of the target antigen in HTLV-I infection. Leukemia 8:S54-S59.
31. tax protein of human T cell leukemia virus 1 and infectivity. J Infect Dis 161:426-429.
32. Katahira Y, Yashiki S, Fujiyoshi T, Noniura K, Tara M, Mori M, Setoyama M, Kanzaki T, Shida H, Sonoda S. 1995. In vitro induction of cytotoxic T lymphocytes against HTLV-I-infected T-cells from adult T-cell leukemia patients, asymptomatic HTLV-I carriers and seronegative healthy donors. Jpn J Cancer Res 86:21-27.
33. Kikkawa E, Miyahara N, Narue TK, Shimada K, Azuma F, Hara H, Inoko H. 2003. Evaluation of the PCK-Luminex method for four-digital level genotyping of the HLA-A, HLA-B and HLA-DRB1 genes in the Japanese population. MHC 10:21-31.
34. Kinoshita K, Amagasaki T, Ikeda S, Suzuyama J, Toriya K, Nishino K, Tagawa M, Ichimaru M, Kamihira S, Yamada Y. 1980. Preleukemic state of adult T cell leukemia: Abnormal T lymphouylosis induced by hunuin adult T cell leukemia-lymphoma virus. Blood 66:120-127.
35. Kinoshita K, Amagasaki T, Hino S, Doi H, Yamanouchi K, Ban N, Momita S, Ikeda S, Kamihira S, Ichimaru M. 1987. Milk-borne transmission of HTLV-I from carrier mothers to their children. Jpn J Cancer Res 78:674-680.
36. Kondo T, Nonaka H, Miyamoto N, Hanaoka M. 1985. Very low percentage flower cell carrier - Can it be an index for pre-leukemic stage for ATLL? Oncologia 12:139.
37. + T cell in adult T cell leukemia patients. J Immunol 177:5718-5726.
38. + lymphocytes directly in peripheral blood of HTLV-I-associated myefopathy/tropical spastic paraparesis patients by intracellular cytokine detection. J Immunol 161:482-488.
39. + lymphocytes correlate with the provirus load in peripheral blood of infected individuals. J Neuroimmunol 102:208-215.
40. Kuzushima K, Hayashi N, Kimuru H, Tsurumi T. 2001. Efficient identification of HLA-A*2402-restricted eytomegalovirus-specific CD8+ T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. Blood 98:1872-1881.
41. Levin MC, Lehky TJ, Flerlage AN, Katz D, Kingma DW, Jaffe ES, Heiss JD, Patronas N, McFarland HF, Jacobson S. 1997. Immunologic analysis of a spinal cord-biopsy specimen from a patient with human T-cell lymphotropic virus type 1-associated neurologic disease. N Engl J Med 336:839.
42. Maloney EM, Blattner WA. 2003. HTLV-I worldwide patterns and disease associations. Gann Monogr Cancer Res 50:339-361.
43. Manns A, Miley WJ, Wilks RJ, Morgan OS, Hanchard B, Wharfe G, Cranston B, Maloney E, Wells SL, Blattner WA, Waters D. 1999. Quantitative proviral DNA and antibody levels in the natural history of HTLV-I infection. J Infect Dis 180:1487-1493.
44. Matter M, Mumprecht S, Pinschewer DD, Pavelic V, Yagita H, Krautwald S, Borst J, Ochsenbein AF. 2005. Virus-induced polyclonal B cell activation improves protective CTL memory via retained CD27 expression on memory CTL. Eur J Immunol 35: 3229-3239.
45. Miyoshi I, Kubonishi I, Yoshimoto S, Shiraishi Y. 1981. A T-cell line derived from normal human cord leukocytes hy co-culturing with human leukemic T-cells. Gann 72:978-981.
46. Nagai M, Usuku K, Matsumoto W, Kodama D, Takenouchi N, Moritoyo T, Hashiguchi S, Ichinose M, Bangham CRM, Izumo S, Osame M. 1998. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: High proviral load strongly predisposes to HAM/TSP. J Neurovirol 4:586-593.
47. Nagai M, Kubota R, Greten TF, Schneck JP, Leist TP, Jacobson S. 2001. Increased activated human T cell lymphotropic virus type I (HTLV-I) Tax11-19-specific memory and effector CD8+ cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis: Correlation with HTLV-I provirus load. J Infect Dis 183:197-205.
48. Niewiesk S, Daenke S, Parker CE, Taylor G, Weher J, Nightingale S, Bangham CR. 1994. The transactivator gene of human T-cell leukemia virus type I is more variable within and between healthy carriers than patients with tropical spastic paraparesis. J Virol 68: 6778-6781.
49. Ogg GS, Jin X, Bonhoeffer S, Dunbar PR, Nowak MA, Monard S, Segal JP, Cao Y, Rowland-Jones SL, Cerundolo V, Hurley A, Markowitz M, Ho DD, Nixon DF, McMichael AJ. 1998. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279:2103-2106.
50. Okayama A, Stuver SO. 2003. Long-term follow-up of HTLV-I carriers. In: Two decades of adult T-cell leukemia and HTLV-I research. Gann Monogr Cancer Res 50:127-139.
51. Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, Matsumoto M, Tara M. 1986. HTLV-I associated myelopathy, a new clinical entity. Lancet 1:1031-1032.
52. Parker CE, Daenke S, Nightingale S, Bangham CR. 1992. Activated, HTLV-I-specific cytotoxic T lymphocytes are found in healthy seropositives as well as in patients with tropical spastic paraparesis. Virology 188:628-636.
53. Parker CE, Nightingale S, Taylor GP, Weber J, Bangham CR. 1994. Circulating anti-Tax cytotoxic T lymphocytes from human T-cell leukemia virus type I-infected people, with and without tropical spastic paraparesis, recognize multiple epitopes simultaneously. J Virol 68:2860-2868.
54. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. 1980. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 77:7415-7419.
55. tax antibody-positive mothers. Jpn J Cancer Res 80:506-508.
56. Schneider J, Yamamoto N, Hinuma Y, Hunsmann G. 1984. Sera from adult T-cell leukemia patients react with envelope and core polypeptides of adult T-cell leukemia virus. Virology 15:1-11.
57. Sonoda S. 2003. Genetic risk of disease development among HTLV-I carriers. Gann Monogr Cancer Res 50:289-301.
58. Sonoda J, Koriyama C, Yamamoto S, Kozako T, Li HC, Lema C, Yashiki S, Fujiyoshi T, Yoshinaga M, Nagata Y, Akiba S, Takezaki T, Yamada K, Sonoda S. 2004. HTLV-1 provirus load in peripheral blood lymphocytes of HTLV-1 carriers is diminished by green tea drinking. Cancer Sci 95:596-601.
59. Tachibana N, Okayama A, Ishihara S, Shioiri S, Murai K, Tsuda K, Goya N, Matsuo Y, Essex M, Stuver S, Mueller N. 1992. High HTLV-I proviral DNA level associated with abnormal lymphocytes in peripheral blood from asymptomatic carriers. Int J Cancer 51:593-595.
60. Tajima K. 1990. The 4th nation-wide study of adult T-cell leukemia/ lymphoma (ATL) in Japan: Estimates of risk of ATL and its geographical and clinical features. The T- and B-cell Malignancy Study Group. Int J Cancer 45:237-243.
61. Taylor GP, Tosswill JH, Matutes E, Daenke S, Hall S, Bain BJ, Davis R, Thomas D, Rossor M, Bangham CR, Weber JN. 1999. Prospective study of HTLV-I infection in an initially asymptomatic cohort. J Acquir Immune Defic Syndr 22:92-100.
62. van Essen D, Dullforce P, Brocker T, Gray D. 2000. Cellular interactions involved in Th cell memory. J Immunol 165:3640-3646.
63. Vine AM, Witkover AD, Lloyd AL, Jeffery KJ, Siddiqui A, Marshall SE, Bunce M, Eiraku N, Izumo S, Usuku K, Osame M, Bangham CR. 2002. Polygenic control of human T lymphotropic virus type I (HTLV-I) provirus load and the risk of HTLV-I-associated myelopathy/tropical spastic paraparesis. J Infect Dis 186:932-939.
64. Wodarz D, Bangham CR. 2000. Evolutionary dynamics of HTLV-I. J Mol Evol 50:448-455.
65. Wodarz D, Hall SE, Usuku K, Osame M, Ogg GS, McMichael AJ, Nowak MA, Bangham CR. 2001. Cytotoxic T-cell abundance and virus load in human immunodeficiency virus type 1 and human T-cell leukaemia virus type 1. Proc R Soc Lond B Biol Sci 268:1215-1221.
66. Yamamoto N, Schneider J, Koyanagi Y, Hinuma Y, Hunsmann G. 1983. Adult T-cell leukemia (ATL) virus-specific antibodies in ATL patients and healthy virus carriers. Int J Cancer 15:281-287.
67. Yao K, Hisada M, Maloney E, Yamano Y, Hanchard B, Wilks R, Rios M, Jacobson S. 2006. Human T lymphotropic virus types I and II western blot seroindeterminate status and its association with exposure to prototype HTLV-I. J Infect Dis 193:427-437.
68. + cytotoxic T lymphocytes. AIDS Res Hum Retroviruses 17:1047-1061.
69. Yokota T, Cho MJ, Tachibana N, McLane M, Takatsuki K, Lee TH. Mueller N, Essex M. 1989. The prevalence of antibody to p42 of HTLV-I among ATLL patients in comparison to healthy carriers in Japan. Int J Cancer 43:970-974.